Literature DB >> 3703301

Fatal metabolic acidosis, hyperglycemia, and coma after steroid therapy for Kearns-Sayre syndrome.

R G Curless, J Flynn, B Bachynski, J B Gregorios, P Benke, R Cullen.   

Abstract

Two adolescent boys with Kearns-Sayre syndrome (progressive external ophthalmoplegia, heart block, elevated CSF protein, and ragged-red muscle fibers) developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria after a brief course of steroid therapy. Both had hyperglycemia and acidosis. Nonketotic, lactic acidosis was present in one and ketosis in the other. Severe respiratory failure developed, and both patients died. Postmortem revealed fatty infiltration of the pancreas in addition to a diffuse spongiform encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3703301     DOI: 10.1212/wnl.36.6.872

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Glucocorticoids for mitochondrial disorders.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Singapore Med J       Date:  2015-02       Impact factor: 1.858

Review 2.  Treatment of mitochondrial disease.

Authors:  R W Taylor; P F Chinnery; K M Clark; R N Lightowlers; D M Turnbull
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

3.  Atypical presentation of multisystem disorders in two girls with mitochondrial DNA deletions.

Authors:  M H Tulinius; A Oldfors; E Holme; N G Larsson; M Houshmand; P Fahleson; L Sigström; B Kristiansson
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

Review 4.  Treatment for mitochondrial disorders.

Authors:  Gerald Pfeffer; Kari Majamaa; Douglass M Turnbull; David Thorburn; Patrick F Chinnery
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 5.  Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.

Authors:  Fahad Aljebab; Imti Choonara; Sharon Conroy
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.